Invesco Dorsey Wright Healthcare Momentum ETF PTH
58.91 USD +1.17 (+2.03%)
At closeNov 3, 2026, 4:00 PM EST
58.99 +0.08 +0.13%
After hours · Nov 3, 4:00 PM ET
58.16 Day range 59.54
46.09 52-week range 64.10
- YTD
- +18.54%
- 1 year
- +22.58%
- Market cap
- 134.75M
- EPS (ttm)
- 1.50
- P/E ratio
- 39.26
- YTD return
- +18.54%
- 1-year return
- +22.58%
- Volume
- 18.54K
- Avg volume
- 39.94K
- Open
- 58.16
- Previous close
- 57.74
- Day's range
- 58.16 – 59.54
- 52-week range
- 46.09 – 64.10
2Y +13.46 (+29.50%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 44.93
- 200-day average
- 44.07
About Invesco Dorsey Wright Healthcare Momentum ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of at least 30 securities of companies in the healthcare sector that have powerful relative strength or "momentum" characteristics.
News
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years 
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting 
Should You Invest in the Invesco Dorsey Wright Healthcare Momentum ETF (PTH)? 
Micot Pharma Reports Positive Operating Cash Flow and Advances Late-Stage Pipeline in 1H 2026 
Moderna Advances Ebola Vaccine Into Human Testing 
Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting 
Should You Invest in the Invesco Dorsey Wright Healthcare Momentum ETF (PTH)? 
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism 
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
Your note
Sign in to keep a note on PTH — it syncs with the Stock Master app.